Adoptive cell therapy (ACT) using T-cells derived from the patient's own tumor, called tumor-infiltrating lymphocytes (TILs), have shown impressive results in the treatment of metastatic melanoma and some other solid tumors. Recent technological advances have enabled the identification of specific mutations in patients' tumors, which are seen as new potential targets for personalized therapy. The research group has developed a personalized TIL-ACT highly enriched with T cells targeting the patient's tumor-specific neoantigens (NeoTIL).

The SAKK 88/20 study will investigate and determine the safety, feasibility and efficacy of this novel approach in the treatment of patients with hypermutated gastrointestinal cancers. In the future, this novel approach could be extended to other hypermutated solid tumors for which no other therapeutic option is available besides palliative care.

The Swiss Foundation for Clinical Cancer Research (SSKK) promotes clinical and epidemiological cancer research in Switzerland. It is financed by private donations and legacies. The foundation board consists of personalities from research and politics, which guarantees the support of practice-oriented research for the benefit of patients.

SAKK 88/20
«A multicenter Single Arm Phase I Trial to Assess the Feasibility, Safety and Efficacy of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes Enriched for Tumor Antigen Specificity (NeoTIL) in Hypermutated Gastrointestinal Cancer.»